Samuel Rubinstein sold $6,678 of MDWD
director at MediWound Ltd.. 525 shares at an average of $12.72, traded Sep 1, 2026, filed Sep 2, 2026.
Score components
- +15RoleDirector
- 0Trade size$7k at market
- +20Share of holdings soldSold 100% of holdings
- +8Cluster2 insiders selling within 14 days
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001178913-26-004392, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Sep 1, 2026 | SOpen-market sale Ordinary Sharesindirect: By spouse | -525 | $12.72 | $6,678 | 0 | 42 d ago |
| Sep 1, 2026 | POpen-market purchase Ordinary Sharesindirect: By spouse | +525 | $12.62 | $6,626 | 525 | 42 d ago |
Related signals
Other insiders at MediWound Ltd. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 23Weak | MDWDbuy MediWound Ltd. | Samuel Rubinstein director | $6,626 525 shares | - | |
| 41Moderate | MediWound Ltd. | Shmuel Hess COO & Chief Commercial Officer | $75k 5,823 shares | -312% | |
| 60Notable | MediWound Ltd. | Nachum Shamir director | $84k 6,000 shares | +12% | |
| 58Moderate | MediWound Ltd. | David Morton Fox director | $50k 3,537 shares | +19% | |
| 51Moderate | MediWound Ltd. | Samuel Rubinstein director | $2,150 150 shares | +5% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.